Tag: pediatric vs adult rare disease gene therapy approval differences
2024 US Guide: Pediatric vs. Adult Rare Disease Gene Therapy Approval, Safety, Insurance, Pipeline & Why Most Treatments Are Approved for Kids
Per FDA 2024, American Academy of Pediatrics (AAP) 2024, and CMS 2024 data, this October 2024 updated buying guide breaks down pediatric vs adult rare disease gene therapy approval, safety, insurance coverage, and pipeline gaps, including premium FDA-compliant regulatory pathways vs counterfeit unvetted off-label treatment models. 68% of 2024 FDA-approved rare disease gene therapies are